購物車 
-
Ascidiacyclamide
- names：
Ascidiacyclamide
- CAS號(hào)：
86701-12-4
MDL Number： - MF(分子式)： C36H52N8O6S2 MW(分子量)： 756.982
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 貨品編碼 | 規(guī)格 | 純度 | 價(jià)格 (￥) | 現(xiàn)價(jià)(￥) | 特價(jià)(￥) | 庫存描述 | 數(shù)量 | 總計(jì) (￥) |
|---|
- 大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
- 收藏商品 商品點(diǎn)評(píng) 加入購物車 立即購買
| 中文別名 | (4S,7R,8S,11R,18S,21R,22S,25R)-4,18-bis[(2S)-butan-2-yl]-7,21-dimethyl-11,25-di(propan-2-yl)-6,20-dioxa-13,27-dithia-3,10,17,24,29,30,31,32-octazapentacyclo[24.2.1.15,8.112,15.119,22]dotriaconta-1(28),5(32),12(31),14,19(30),26(29)-hexaene-2,9,16,23-tetrone |
| 英文別名 | Ascidiacyclamide |
| CAS號(hào) | 86701-12-4 |
| Inchi | InChI=1S/C36H52N8O6S2/c1-11-17(7)25-33-43-27(19(9)49-33)31(47)39-24(16(5)6)36-38-22(14-52-36)30(46)42-26(18(8)12-2)34-44-28(20(10)50-34)32(48)40-23(15(3)4)35-37-21(13-51-35)29(45)41-25/h13-20,23-28H,11-12H2,1-10H3,(H,39,47)(H,40,48)(H,41,45)(H,42,46)/t17-,18-,19+,20+,23+,24+,25-,26-,27-,28-/m0/s1 |
| InchiKey | QBRRPBPLIGDANJ-AXCFFLBZSA-N |
| 分子式 Formula | C36H52N8O6S2 |
| 分子量 Molecular Weight | 756.982 |
| 溶解度Solubility | |
| 性狀 | Solid powder |
| 儲(chǔ)藏條件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 產(chǎn)品說明 | Ascidiacyclamide(CAS:86701-12-4):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。 |
| Introduction | Ascidiacyclamide is a cytotoxic cyclic peptide from the marine tunicate Ascidian. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Jaspars M. The origins of cyanobactin chemistry and biology. Chem Commun (Camb). 2014 Sep 14;50(71):10174-6. doi: 10.1039/c3cc49252d. Review. PubMed PMID: 25068542. |
| [2]Comba P, Gahan LR, Hanson GR, Maeder M, Westphal M. Carbonic anhydrase activity of dinuclear Cu(II) complexes with patellamide model ligands. Dalton Trans. 2014 Feb 28;43(8):3144-52. doi: 10.1039/c3dt53135j. PubMed PMID: 24326405. |
| [3] Asano A, Minoura K, Yamada T, Doi M. Conformational transformation of ascidiacyclamide analogues induced by incorporating enantiomers of phenylalanine, 1-naphthylalanine or 2-naphthylalanine. J Pept Sci. 2016 Mar;22(3):156-65. doi: 10.1002/psc.2853. PubMed PMID: 26856689. |
| [4] Asano A, Yamada T, Doi M. Modulating the structure of phenylalanine-incorporated ascidiacyclamide through fluorination. J Pept Sci. 2014 Oct;20(10):794-802. doi: 10.1002/psc.2668. Epub 2014 Jul 1. PubMed PMID: 24985333. |
| [5] Asano A, Doi M, Kobayashi K, Arimoto M, Ishida T, Katsuya Y, Mezaki Y, Hasegawa H, Nakai M, Sasaki M, Taniguchi T, Terashima A. Effects of amino acids and chirality for molecular folding of desoxazoline-ascidiacyclamide derivatives: X-ray crystal structures of four cyclic octapeptides including unusual amino acids, cyclo(-Ile-aThr-D-Val-Thz-)(2), cyclo(-Ala-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), cyclo(-Val-aThr-D-Val-Thz-Ile-aThr-D-Val-Thz-), and cyclo(-Ile-aThr-Val-Thz-Ile-aThr-D-Val-Thz-). Biopolymers. 2001 Mar;58(3):295-304. PubMed PMID: 11169389. |
6: Asano A, Numata S, Yamada T, Minoura K, Doi M. Conformational properties of ascydiacyclamide analogues with cyclic α-amino acids instead of oxazoline residues. Bioorg Med Chem. 2017 Dec 15;25(24):6554-6562. doi: 10.1016/j.bmc.2017.10.029. Epub 2017 Oct 26. PubMed PMID: 29097029.7: Doi M, Shinozaki F, In Y, Ishida T, Yamamoto D, Kamigauchi M, Sugiura M, Hamada Y, Kohda K, Shioiri T. Conformational change of ascidiacyclamide caused by asymmetric modification for an isoleucine residue: structural analyses of [Gly], [Leu], and [Phe]ascidiacyclamides by x-ray diffraction and NMR spectroscopy. Biopolymers. 1999 May;49(6):459-69. PubMed PMID: 10193193.8: Asano A, Yamada T, Doi M. The square conformation of phenylglycine-incorporated ascidiacyclamide is stabilized by CH/π interactions between amino acid side chains. Bioorg Med Chem. 2011 Jun 1;19(11):3372-7. doi: 10.1016/j.bmc.2011.04.036. Epub 2011 Apr 22. PubMed PMID: 21592800.9: Asano A, Yamada T, Numata A, Doi M. Cyclo(-Cha-Oxz-D-Val-Thz-Ile-Oxz-D-Val-Thz-) N,N-dimethylacetamide dihydrate: a square form of cyclohexylalanine-incorporated ascidiacyclamide having the strongest cytotoxicity. Acta Crystallogr C. 2003 Sep;59(Pt 9):o488-90. Epub 2003 Aug 9. PubMed PMID: 12944653.10: Ishida T, In Y, Doi M, Inoue M, Hamada Y, Shioiri T. Molecular conformation of ascidiacyclamide, a cytotoxic cyclic peptide from Ascidian: X-ray analyses of its free form and solvate crystals. Biopolymers. 1992 Feb;32(2):131-43. PubMed PMID: 1637988.1
對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關(guān)產(chǎn)品
-
< >
- 推薦產(chǎn)品
-
< >
- 最新產(chǎn)品
-
< >
新聞
胞爬片免疫組化染色.png)
怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)
細(xì)胞爬片免疫組化染色，是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi)，細(xì)胞在玻片上生長(zhǎng)，主要用于組織學(xué)，免疫組織化學(xué)...
2020/7/20 22:04:33
提取病毒RNA的實(shí)驗(yàn)方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
胞插件.png)
細(xì)胞培養(yǎng)耗材技術(shù)領(lǐng)先性
細(xì)胞培養(yǎng)板行業(yè)面臨的核心痛點(diǎn)是：常規(guī)TC處理后表面親水角隨時(shí)間衰減，影響長(zhǎng)期培養(yǎng)穩(wěn)定性，BIOFOUNT高分...
2026/4/28 15:12:51
胞培養(yǎng)板.jpg)
細(xì)胞培養(yǎng)耗材關(guān)鍵性能
細(xì)胞培養(yǎng)板的水接觸角作為表面潤(rùn)濕性的核心指標(biāo)，直接影響細(xì)胞貼壁、增殖、分化及功能表達(dá)，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽離子的偏好。它對(duì)二價(jià)...
2025/11/4 14:22:46
9月開學(xué)季——助研新學(xué)期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實(shí)驗(yàn)室封口膜：技術(shù)與國(guó)際市場(chǎng)的雙重突破
在實(shí)驗(yàn)室耗材領(lǐng)域，封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來，Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實(shí)驗(yàn)室封口膜的5大突破
Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破，是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個(gè)重要環(huán)節(jié)，也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是：微流控...
2023/7/27 12:44:28
